Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib

Severe aplastic anemia (SAA) is a rare disease in which the bone marrow cannot produce adequate supplies of cells. A more recent and curative approach to SAA includes allogenic hematopoietic stem-cell transplantation (allo-HCT). Graft-vs-host disease (GVHD) is one of the most frequent complications of allo-HCT and is associated with high morbidity and mortality.¹ In both its acute and chronic subtypes, GVHD manifests in multiple organs. Chronic GVHD affects 30% to 70% of patients, with an onset of 4 to 6 months after transplant.²